Crohn’s Disease
Crohn’s Disease
Crohn’s Disease is a chronic inflammatory bowel disease that can affect any part of the gastrointestinal tract. This category helps you compare prescription options used to control flares and keep remission stable, with US shipping from Canada available on eligible items. You can review biologics, immunomodulators, corticosteroids, and select aminosalicylates across infusion, injection, and oral forms. Compare common dosing schedules, dosage strengths, storage needs, and monitoring basics in one place. Stock and selection can vary over time, and listings may change without notice.
What’s in This Category
This section organizes therapies by class, format, and common use case. You will find Crohn’s disease medications across key groups, including anti-TNF inhibitors, IL‑12/23 inhibitors, JAK inhibitors, immunomodulators, and corticosteroids. Infusion products are typically given in a clinic or infusion suite at set intervals. Prefilled pens or syringes allow home injections on weekly or monthly schedules. Oral options may be used for short-term control or as adjuncts in select patients.
Biologics are targeted monoclonal antibodies that block inflammatory signals. Anti-TNF agents reduce tumor necrosis factor activity to lower intestinal inflammation. IL‑12/23 blockers act upstream on cytokines that drive the immune response. JAK inhibitors are small molecules taken by mouth that modulate intracellular signaling. Immunomodulators like azathioprine help maintain remission but require lab monitoring. Corticosteroids can induce remission quickly, but long-term risks limit continuous use. Aminosalicylates have a limited role in Crohn’s compared with ulcerative colitis.
How to Choose
Selection usually depends on disease severity, location, and prior response. Induction aims to calm active inflammation fast; maintenance aims to sustain remission with fewer side effects. Home administration versus infusion-center care may influence scheduling and support needs. Safety considerations include infection risk, vaccination status, pregnancy planning, and history of malignancy. Storage and handling matter, because many biologics need refrigeration and protection from light. When lab monitoring is required, build those intervals into your routine.
Discuss a plan that balances fast control with long-term safety and convenience. For many adults, the main decision is choosing a steroid-sparing option for Crohn’s disease maintenance therapy. Consider how quickly the medicine works, needed pre-medications, and potential drug interactions. Ask about biosimilar availability where appropriate, and learn how to transition if a switch is recommended. For injections or infusions, clarify needle size, device type, and administration time so the routine fits your life.
- Common mistake: relying on steroids longer than needed for maintenance.
- Common mistake: skipping baseline screening (TB, hepatitis) before starting biologics.
- Common mistake: improper storage leading to reduced potency or waste.
Popular Options
Anti-TNF infusions such as infliximab are established choices for moderate to severe disease, including fistulizing presentations. Loading doses are followed by maintenance at fixed intervals in a clinic setting. Home injection options include adalimumab and certain biosimilars, delivered by prefilled pen or syringe. These options suit those comfortable with self-administration who want steady spacing between doses.
Cytokine-targeted agents include ustekinumab, which blocks IL‑12 and IL‑23. It often begins with a one-time IV induction, followed by subcutaneous maintenance every 8 to 12 weeks. JAK inhibitors offer a tablet form for systemic control, with dose adjustments across induction and maintenance phases. Together, these Crohn’s disease biologics and small molecules expand options for patients who did not respond to earlier treatments or need different safety profiles.
Traditional immunomodulators such as azathioprine or 6‑mercaptopurine may support remission in select cases. They require TPMT/NUDT15 consideration and routine bloodwork to watch for myelosuppression or liver effects. Budesonide can help with ileocecal involvement as a localized steroid option, though it is not a long-term maintenance strategy. Your clinician may combine approaches briefly during transitions, tapering steroids as control improves.
Related Conditions & Uses
Inflammatory bowel disease spans Crohn’s and ulcerative colitis, which share symptoms but differ in distribution and depth of inflammation. Many principles of IBD treatment for Crohn’s apply to complex patterns such as fistulizing disease or stricturing phenotypes. Perianal disease often needs a coordinated approach with imaging, seton placement when needed, and biologics with evidence for fistula closure. Postoperative prevention strategies focus on reducing recurrence at the anastomosis, guided by risk factors and endoscopic monitoring.
Extraintestinal manifestations may involve skin, eyes, joints, or hepatobiliary systems. When selecting therapy, consider options that treat both gut inflammation and relevant extraintestinal features. Vaccination review is important prior to immunosuppression, and live vaccines are typically avoided during treatment. Nutritional support, iron repletion, and bone health also matter, especially when prior steroid exposure or malabsorption is present. Ongoing follow-up helps align therapy with evolving goals, from symptom control to mucosal healing.
Authoritative Sources
For an overview of current guideline recommendations, see the American Gastroenterological Association’s guidance for moderate to severe Crohn’s disease management covering induction and maintenance decisions. FDA resources describe safety considerations for TNF blockers and other immunosuppressants; review background materials on class risks before starting or switching therapy. The National Institute of Diabetes and Digestive and Kidney Diseases provides patient-friendly education on Crohn’s and its treatments including Crohn’s disease flare treatment basics.
Medical disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice.
Filter
Product price
Product categories
Conditions
Select options
This product has multiple variants. The options may be chosen on the product page
Select options
This product has multiple variants. The options may be chosen on the product page
Promotion
Stelara Prefilled Syringe
Price range: $6,180.99 through $6,798.99
You save
- In Stock
- Express Shipping
Select options
This product has multiple variants. The options may be chosen on the product page
Frequently Asked Questions
Do Crohn’s biologics need refrigeration during shipping?
Yes, most biologic injections require cold-chain handling from the pharmacy to delivery. They are shipped with insulated packaging and cold packs to maintain 2–8°C until arrival. After delivery, store them in a refrigerator as directed and avoid freezing. Keep the product in its original carton to protect it from light. Before injecting, allow it to reach room temperature per the instructions. Always check the carton and solution for damage or discoloration before use.
Can I browse options without a prescription on this page?
You can browse classes, formats, and strengths without a prescription, but dispensing prescription medicines requires a valid script. Your prescriber specifies the medication, dose, and route that match your history. Pharmacies verify details before filling. Over-the-counter products may appear in related categories, but they do not replace prescription therapy. Use this page to understand formats, storage basics, and monitoring needs before discussing choices with your clinician.
How do infusion treatments compare with home injections?
Infusions are given at set intervals in a clinic and include monitoring during and after the dose. They suit patients who prefer supervised administration. Home injections rely on training with pens or syringes and allow flexible scheduling at home. They often require refrigeration and careful preparation. Choice depends on disease control needs, access to infusion services, and comfort with self-injection. Both approaches need periodic lab work and follow-up to assess response and safety.
When are steroids used for Crohn’s?
Steroids are typically used for short-term induction when symptoms flare. They reduce inflammation quickly, then are tapered to limit side effects. Long-term maintenance on steroids is avoided because of bone loss, glucose changes, and infection risk. Budesonide may help localized ileocecal disease with fewer systemic effects, but it is still not a maintenance solution. Discuss a steroid-sparing plan that transitions to immunomodulators or biologics for durable control.
What should I consider before switching to a biosimilar?
Switching involves confirming the biosimilar’s dosing, device format, and interchangeability policy in your region. Review prior response, adverse effects, and timing of your last dose. Plan lab monitoring or drug level testing if appropriate. Ensure pharmacy coordination to prevent gaps in therapy, and confirm storage and injection training for the new product. Report any changes in disease control after the switch so your care team can adjust the plan if needed.
Related Articles
Cancer, Dermatology
Ustekinumab vs Adalimumab: Safer Choice for Malignancy Risk
When comparing ustekinumab vs adalimumab, safety around malignancy (cancer) matters for long-term care. This review explains mechanisms, current evidence, and practical factors that shape risk. Use it to frame discussions…
Dermatology
Stelara Guide: Ustekinumab Uses, Benefits, and Cost Comparison
Key TakeawaysStelara treats select immune-mediated conditions and offers spaced maintenance dosing.It targets interleukin pathways to help calm inflammatory activity in skin and gut.Discuss infection risk, lab screening, and vaccination timing…